drugset / Trial / NCT03785184
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM). This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Timeline
- Start
- 2019-04-29
- Primary completion
- 2019-08-22
- Completion
- 2019-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | 800 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 25 mg | Oral |